← boardnext 2026-11-30
BIOA
BioAge Labs, Inc.distress 1/10 · well-funded / low risk$21.50-2%today-14% from 52w high
Metabolic / Obesity 1
Lead: cardiovascular risk · target GLP-1/GIP
Revenue
pre-revenue
Liquidity
$385M
Runway
4.4 yrs
Shares 1y
+24%
Price & events
+13.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.0%
1D
-3.0%
1W
-3.7%
1M
+24.7%
3M
+14.3%
6M
+343.3%
1Y
—
2Y
—
5Y
+17.4%
All
Overview
- Market Cap
- $955.73M
- Enterprise Value
- $713.96M
- Volume
- 15.28K
- 52 Week Range
- $4.12 – $25.10
- Total Shares
- 44.45M
- Float Shares
- 34.95M
- Short %
- 9.51%
- % Held by Insiders
- 2.44%
- % Held by Institutions
- 85.07%
- RVOL
- 0.02x
Pipeline stages · 2 programs
Oral BGE-102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Oral Azelaprag (BGE-105), TirzepatideGLP-1/GIP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-30 Estimated 50% readout ~2027-01-14 | Phase 2 | Oral BGE-102 | Obesity and Cardiovascular Risk | — | recruiting |
| 2025-02-06 | Phase 2 | Oral Azelaprag (BGE-105), Tirzepatide | Obesity | 204 | terminated |
Catalyst news & presentations · 10
- end of 2027Guided 40%trial initiationsecondaryPhase 3BGE-102 · Phase 3 registration study initiationSEC 8-K
- mid-2027Guided 55%readoutPhase 1/2BGE-102 · DME Phase 1b/2a POC trial data readoutSEC 8-K
- end of 2026Guided 40%regulatory submissionFiled (NDA/BLA)APJ agonist · IND application submissionSEC 8-K
- 2H 2026Guided 55%readoutPhase 2BGE-102 · CV risk Phase 2a POC trial data readoutSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 1H 2026trial initiationsecondaryPhase 2BGE-102 · Initiation of Phase 2a proof-of-concept studySEC 8-K
- 1H 2026readoutPhase 1BGE-102 · Completion of Phase 1 trial with full data readoutSEC 8-K
- second half of 2026readoutPhase 1NLRP3 program · Obesity proof-of-concept dataSEC 8-K
- end of yearreadoutPhase 1NLRP3 program · Initial SAD dataSEC 8-K
- mid-2025trial initiationsecondaryPhase 1NLRP3 program · IND submission and initiation of Phase 1 SAD/MAD trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $50 (+130% upside) · 8 analysts
- 2026-05-27Roth CapitalBuy
- 2026-05-13BTIGBuy
- 2026-03-27NeedhamBuy
- 2026-03-10CitigroupBuy
- 2026-02-25OppenheimerOutperform
- 2026-02-18JefferiesHold → Buy
Competitors — GLP-1/GIP
Recent news
- 2026-07-20BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
- 2026-07-19Price to earnings forward of BioAge Labs, Inc. – FWB:Y7G - TradingView
- 2026-07-14HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction - PR Newswire
- 2026-07-14Price to book forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
- 2026-07-10BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment - Traders Union
- 2026-07-10How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure - Sahm
- 2026-07-10How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure - simplywall.st
- 2026-07-07Price to sales forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.